Cure8 research brief
If pre‑treatment biopsy features predict response to ustekinumab, clinicians might better select which UC patients are likely to benefit, potentially avoiding ineffective therapy for some and speeding effective treatment for others.
This study offers early data pointing to neutrophil and eosinophil levels as candidate markers, especially in patients without prior advanced‑therapy exposure.
Clinicians treating ulcerative colitis, researchers studying predictive biomarkers or personalized IBD therapy, and patients considering or starting ustekinumab (especially those who are biologic‑naive).
This is an exploratory, small, retrospective study from one center using archived biopsy histology and clinical outcome data after ustekinumab.
The findings suggest certain pre‑treatment cellular features on biopsy (neutrophil and eosinophil levels) might correlate with short‑ and longer‑term response in patients who had not previously received advanced biologic/small‑molecule therapies. These results are preliminary and hypothesis‑generating.
They do not establish that biopsy features should yet guide treatment choices. Larger, prospective studies would be needed to confirm whether histology can reliably predict ustekinumab benefit and to define usable thresholds or scoring for clinical practice.
If you are a patient, clinician, or researcher, consider this as early evidence that tissue-level inflammatory patterns could inform personalized therapy strategies, but not as definitive guidance for individual treatment decisions.
This is a small, retrospective pilot study from a single center (n=33) with subgroup analyses; findings are exploratory and need confirmation in larger, prospective cohorts before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
